Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton Dickinson (BDX) delivered earnings and revenue surprises of 11.38% and 8.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Becton Dickinson (BDX) Q3 Earnings and Revenues Surpass Estimates

Becton Dickinson and Co (NYSE: BDX) reported Q3 revenues of $4.9 billion, +26.9% Y/Y, better than the consensus of $4.51 billion. The increase is primarily driven by the strong base business performance as overall healthcare utilization levels recover from the initial impact of COVID-19.

BDX Stock Plunges Despite Q3 Earnings Topping Estimates On Recovery In Elective Volumes; Raised FY21 Guidance

Shares of Becton, Dickinson (NYSE:BDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were up 24.55% year over year to $2.74, which beat the estimate of $2.44.

Becton, Dickinson: Q3 Earnings Insights

FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ -- Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis.

BD Announces Third Fiscal Quarter Results; Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021

FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher Reidy, 64, executive vice president, chief financial officer (CFO) and chief administrative officer (CAO), has informed the company of his intent to retire as he reaches retirement eligibility.

Christopher Reidy Announces Intent to Retire from BD

FRANKLIN LAKES, N.J., July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that management will be presenting at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 2021, at 4:00 p.m.

BD to Present at UBS Genomics 2.0 and MedTech Innovations Summit

FRANKLIN LAKES, N.J., July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the company will begin remediation for the February 4, 2020 BD Alaris™ System 1  recall through a new version of software.

BD to Begin Remediation for BD Alaris™ System Software

Abbott Labs

Johnson & Johnson

You shouldn't invest your life savings into any one stock, but these three have some serious potential.

3 Dividend Stocks Safe Enough to Bet the Farm On

Cardinal Health

Medtronic

You can combine high-quality companies with mega-trends that are favorable for long-term growth with these dividend healthcare stocks. The post 3 Healthcare Stocks for Dividend Growth appeared first on InvestorPlace.

3 Healthcare Stocks for Dividend Growth

FRANKLIN LAKES, N.J., July 27, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

BD Acquires Tepha, Inc., to Drive New Innovations in Soft Tissue Repair and Regeneration

DALLAS, July 23, 2021 /PRNewswire/ -- For the fourth time since May, jurors in federal court have found that C.R. Bard's IVC blood clot filter is defective and responsible for injuries and complications.

Federal Jury in Dallas Finds Bard's IVC Blood Clot Filter Defective and Dangerous

FRANKLIN LAKES, N.J., July 20, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital Stay," building on its history of innovation and leadership in blood collection and vascular access solutions.

BD Seeks to Transform Patient Experience through Vision of 'One-Stick Hospital Stay'

American Tower

Boston Scientific

S&P Global

Barron's, a famous weekly financial newspaper, organizes an annual roundtable with prominent U.S. investors where they discuss the market and give their opinions on their best ideas for stocks.

Parnassus' Roundtable Stock Picks

BD's (BDX) latest online marketplace is expected to offer a better user experience to its flow cytometry users.

BD's (BDX) Digital Marketplace Set to Improve User Experience

FRANKLIN LAKES, N.J., July 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that David F.

BD Announces Two Future Directors for Diabetes Care Spinoff Company

FRANKLIN LAKES, N.J., July 7, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of a new bdbiosciences.com web and eCommerce site, an entirely "reimagined" digital marketplace designed to provide an enhanced online purchasing experience for users and their procurement teams.

BD Launches Reimagined Digital Marketplace for Flow Cytometry

Clorox

Invesco Dow Jones Industrial Average Dividend ETF

Ecolab

Iron Mountain

Markets have become choppy due to inflation and uncertainty. These dividend stocks could provide a safe haven in volatile times for the rest of the year.

The 7 Best Dividend Stocks to Buy for Income Investors In July 2021

FRANKLIN LAKES, N.J., June 30, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the third quarter of fiscal year 2021 on Thursday, August 5, 2021.

BD To Announce Financial Results For Its Third Quarter Of Fiscal 2021

Becton, Dickinson's reported non-GAAP earnings exclude a large amount of unusual items, some of which involve real monetary outlays.

Becton, Dickinson And Company: Improved Return Prospects, It's A Buy

BD's (BDX) receipt of the expanded FDA indication for its PeritX System is expected to lessen the number of hospital trips a patient takes for fluid removal.

BD's (BDX) PeritX System Gets FDA's Expanded 510(k) Clearance

FRANKLIN LAKES, N.J., June 23, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the PeritX™ Peritoneal Catheter System for the drainage of symptomatic, recurrent non-malignant ascites.

BD Announces Expanded 510(k) Clearance for At-Home System for Ascites

FRANKLIN LAKES, N.J., June 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2020 Sustainability Report, highlighting significant achievements in environmental, social and governance (ESG) factors that supported the company's 2020 Sustainability Goals – a five year strategy that concluded in 2020.

BD Highlights Five-Year ESG Achievements in 2020 Sustainability Report, Setting the Foundation for 2030+ Strategy

Edwards Lifesciences

Merit Medical Systems

These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.

Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on

Henry Schein

Veeva Systems

Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.

Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch

BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.

News for Becton, Dickinson and Co. Stock (BDX)